A randomized, double-blind, placebo-controlled, pharmacokinetic and pharmacodynamic study of a fixed-dose combination of phentermine/topiramate in adolescents with obesity.
Daniel S HsiaNathalie H GosselinJenna WilliamsNada FarhatJ F MarierWinnie ShihCraig PetersonRobert SiegelPublished in: Diabetes, obesity & metabolism (2019)
Treatment of adolescents with obesity using a fixed-dose combination of PHEN/TPM for 8 weeks resulted in exposure to PHEN and TPM that was comparable to that observed in adults, statistically significant weight loss, and a tolerable safety profile. These data indicate that both mid- and top-dose levels are appropriate for longer-term safety and efficacy studies in adolescents.
Keyphrases
- weight loss
- young adults
- placebo controlled
- double blind
- physical activity
- bariatric surgery
- insulin resistance
- metabolic syndrome
- type diabetes
- roux en y gastric bypass
- weight gain
- clinical trial
- high fat diet induced
- gastric bypass
- gestational age
- phase iii
- electronic health record
- adipose tissue
- machine learning
- big data
- rectal cancer
- preterm birth